C3a, a vital component in innate immunity, central to complement activation, rapidly converts in serum to its stable form, C3a-desArg, offering a reliable measure of immune response. This transformation is key for researchers tracking inflammation and immune reactions in conditions like sepsis, heart disease, and autoimmune disorders. Our precision-focused human C3a ELISA kit, targeting a unique neo-epitope on C3a-desArg, guarantees accurate results without interference from C3. This makes C3a an indispensable biomarker for groundbreaking immunological research.
The human C3a ELISA kit is to be used for the in vitro quantitative determination of human C3a/C3a-desArg in serum, plasma, bronchoalveolar lavage fluid (BALF) and urine samples.
The human C3a ELISA is a ready-to-use solid-phase enzyme-linked immunosorbent assay based on the sandwich principle with a working time of 3½ hours.
The efficient format of 2 plates with twelve disposable 8-well strips allows free choice of batch size for the assay.
Samples and standards are incubated in microtiter wells coated with antibodies recognizing human C3a.
Biotinylated tracer antibody will bind to captured human C3a.
Streptavidin-peroxidase conjugate will bind to the biotinylated tracer antibody.
Streptavidin-peroxidase conjugate will react with the substrate, tetramethylbenzidine (TMB).
The enzyme reaction is stopped by the addition of oxalic acid.
The absorbance at 450 nm is measured with a spectrophotometer. A standard curve is obtained by plotting the absorbance (linear) versus the corresponding concentrations of the human C3a standards (log).
The human C3a concentration of samples, which are run concurrently with the standards, can be determined from the standard curve.